1 / 16

Supplemental Data for:

Supplemental Data for: Metabolism of Flumatinib, a Novel Antineoplastic Tyrosine Kinase Inhibitor, in Chronic Myelogenous Leukemia Patients by Aishen Gong, Xiaoyan Chen, Pan Deng and Dafang Zhong Drug Metabolism and Disposition. Figure S1 1 H NMR spectrum of M0.

lumina
Télécharger la présentation

Supplemental Data for:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Data for: Metabolism of Flumatinib, a Novel Antineoplastic Tyrosine Kinase Inhibitor, in Chronic Myelogenous Leukemia Patients by Aishen Gong, Xiaoyan Chen, Pan Deng and Dafang Zhong Drug Metabolism and Disposition

  2. Figure S1 1H NMR spectrum of M0

  3. Figure S2 1H NMR spectrum of M0

  4. Figure S3 13C NMR spectrum of M0

  5. Figure S4 13C NMR spectrum of M0

  6. Figure S5 1H NMR spectrum of M2-9

  7. Figure S6 1H NMR spectrum of M2-9

  8. Figure S7 13C NMR spectrum of M2-9

  9. Figure S8 13C NMR spectrum of M2-9

  10. Figure S9 1H NMR spectrum of M4

  11. Figure S10 13C NMR spectrum of M4

  12. Figure S11 1H NMR spectrum of M10

  13. Figure S12 13C NMR spectrum of M10

  14. urine_blank 1: TOF MS ES+ 23.05 579.244 0.05Da 100 20.4 % 0 Time 15.00 16.00 17.00 18.00 19.00 20.00 21.00 22.00 23.00 24.00 25.00 urine 1: TOF MS ES+ 16.59, M2-1 579.244 0.05Da 100 1.37e3 20.91, M2-8 22.21, M2-9 % 18.90, M2-5 19.11, M2-6 20.20, M2-7 18.11, M2-4 0 15.00 16.00 17.00 18.00 19.00 20.00 21.00 22.00 23.00 24.00 25.00 urine_TiCl3 1: TOF MS ES+ 20.90, M2-8 579.244 0.05Da 100 901 % 18.87, M-5 18.08, M2-4 20.16, M2-7 0 15.00 16.00 17.00 18.00 19.00 20.00 21.00 22.00 23.00 24.00 25.00 Figure S13 Extracted ion chromatograms of m/z 579.244 in human urine. A, blank urine; B, urine sample unreduced by TiCl3; C, urine sample reduced by TiCl3

  15. feces 1: TOF MS ES+ 21.93, M2-9 579.244 0.05Da 100 778 17.76, M2-4 % 17.41, M2-3 18.55, M2-5 20.72, M2-8 17.03, M2-2 19.90, M2-7 16.34, M2-1 19.09, M2-6 0 Time 15.00 16.00 17.00 18.00 19.00 20.00 21.00 22.00 23.00 24.00 25.00 feces_TiCl3 1: TOF MS ES+ 17.74, M2-4 579.244 0.05Da 100 461 17.38, M2-3 % 18.50, M2-5 20.67, M2-8 16.96, M2-2 19.88, M2-7 24.51 0 15.00 16.00 17.00 18.00 19.00 20.00 21.00 22.00 23.00 24.00 25.00 Figure S14 Extracted ion chromatograms of m/z 579.244 in human feces. A, feces sample unreduced by TiCl3; B, feces sample reduced by TiCl3.

  16. urine_blank 1: TOF MS ES+ 319.13 0.05Da 100 1.31e3 % 0 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 urine 1: TOF MS ES+ 7.64 319.13 0.05Da 100 2.28e4 14.75, M6 14.33 10.02 % 6.76 8.37 8.74 0 Time 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 urine_TiCl3 1: TOF MS ES+ 7.62 319.13 0.05Da 100 2.16e4 10.00 14.33 % 6.87 8.72 0 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 Figure S15 Extracted ion chromatograms of m/z 319.130 in human urine. A, blank urine; B, urine sample unreduced by TiCl3; C, urine sample reduced by TiCl3.

More Related